维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

4篇 您的检索式：作者名="Robert Eiber"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging显示文摘	Matthias Eiber Ambros J. Beer Konstantin Holzapfel Robert Tauber Carl Ganter Gregor Weirich Bernd J. Krause Ernst J. Rummeny Jochen Gaa	2010	Investigative Radiology2010，，1：	1
	2	Don~t drop the drop - weight tear test 显示文摘	Andrew Cosham David G Jones Robert Eiber	2010	The Journal of Pipeline Engineering2010，，9：	1
	3	Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging显示文摘	Matthias Eiber Ambros J. Beer Konstantin Holzapfel Robert Tauber Carl Ganter Gregor Weirich Bernd J. Krause Ernst J. Rummeny Jochen Gaa	2010	Investigative Radiology2010，，1：	1
	4	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer显示文摘Objective:Cytoreductive radical prostatectomy(cRP)has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer(mHSPC)to prevent local complications and potentially improve oncological outcomes.In this study,we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment,postoperative complication rates,as well as early postoperative continence.Methods:In this retrospective study,38 patients with mHSPC underwent cRP after primary chemohormonal therapy(3-monthly luteinising hormone-releasing hormone-analogue+six cycles 3-weekly docetaxel 75 mg/m2)at two centers between September 2015 and December 2018.Results:Overall,10(26%)patients had high volume and 28(74%)patients had low volume disease at diagnosis,according to CHAARTED definition.Median prostate-specific antigen(PSA)decreased from 65 ng/mL(interquartile range[IQR]35.0-124.5 ng/mL)pre-chemotherapy to 1 ng/mL(IQR 0.3-1.7 ng/mL)post-chemotherapy.Prostate gland volume was significantly reduced by a median of 50%(IQR 29%-56%)under chemohormonal therapy(p=0.003).Postoperative histopathology showed seminal vesicle invasion in 33(87%)patients and negative surgical margins in 17(45%)patients.Severe complications(Grade 3 according to Clavien-Dindo)were observed in 4(11%)patients within 30 days.Continence was reached in 87%of patients after 1 month and in 92%of patients after 6 months.Median time to castration-resistance from begin of chemohormonal therapy was 41.1 months and from cRP was 35.9 months.Postoperative PSA-nadir≤1 ng/mL versus>1 ng/mL was a significant predictor of time to castration-resistance after cRP(median not reached versus 5.3 months;p<0.0001).Conclusion:We observed a reduction of prostate volume under chemohormonal therapy going along with a low postoperative complication and high early continence rate.However,the oncologic benefit from cRP is still under evaluation.	Christa Babst Thomas Amiel Tobias Maurer Sophie Knipper Lukas Lunger Robert Tauber Margitta Retz Kathleen Herkommer Matthias Eiber Gunhild von Amsbergb Markus Graefen Juergen Gschwend Thomas Steuber Matthias Heck	2022	Asian Journal of Urology2022，9，1：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费